Central Pharmaceutical Joint Stock Company No3 (FORIPHARM) is a Vietnam-based company operating in the pharmaceutical industry, which is mainly engaged in the manufacture and trading of pharmaceutical products. The Company's leading products include botanical medicine and other types of drugs, health supplements and cosmetics, among others. Besides, the Company partakes in the commerce of medical equipment and supplies, as well as the conduct of medical research.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	₫61,200.00	+0.16%	3,225
26-07-23	₫61,100.00	0.00%	13,042
26-07-22	₫61,100.00	-2.08%	6,824
26-07-21	₫62,400.00	+1.30%	8,102
26-07-20	₫61,600.00	0.00%	3,800

End-of-day quote HANOI S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote HANOI S.E. Other stock markets 2026-07-24			5-day change	1st Jan Change
61,200.00 ^VND	+0.16%		-0.65%	+15.91%

07-23	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
04-21	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1,316B 50M 43.42M 40.79M 36.84M 71.05M 4.83B 71.05M 484M 189M 2.37B 188M 184M 8.18B	P/E 2024	10.3x	P/E 2025	7.27x
Enterprise Value	875B 33.23M 28.86M 27.11M 24.49M 47.23M 3.21B 47.23M 322M 126M 1.57B 125M 122M 5.44B	EV / Sales 2024	2.18x	EV / Sales 2025	1.58x
Free-Float	22.52%	Yield 2024	5.15%	Yield 2025	7.58%

07-23	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
04-21	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01-21	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-10-20	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-07-18	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-04-18	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-01-19	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
24-07-22	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-04-22	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-01-23	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
23-10-23	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-07-24	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-04-21	Central Pharmaceutical Joint Stock Company No3 Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

1 day	+0.16%
1 week	-0.65%
Current month	-3.62%
1 month	-1.45%
3 months	+5.34%
6 months	-3.16%
Current year	+15.91%

Central PharmaceuticalNo3 Stock

Stocks

DP3

VN000000DP36

Pharmaceuticals

Valuation: Central PharmaceuticalNo3

Chart: Central PharmaceuticalNo3

Latest news : Central PharmaceuticalNo3

Quotes and Performance

Course Extremes

Managers and Directors: Central PharmaceuticalNo3

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	60,500	67,500
1 month	60,500	67,500
Current year	52,000	67,500
1 year	47,000	67,500
3 years	47,000	77,000
5 years	34,800	80,800
10 years	10,600	80,800

Manager	Title	Age	Since
Khai Dinh Nguyen CEO	Chief Executive Officer	50	2019-05-31
Ha Thu Thi Tran AUD	Comptroller/Controller/Auditor	-	2019-07-17

Director	Title	Age	Since
Huong Xuan Bui CHM	Chairman	65	2011-12-31
Cuong Van Dinh BRD	Director/Board Member	62	2014-04-23
Khai Dinh Nguyen BRD	Director/Board Member	50	2017-02-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CENTRAL PHARMACEUTICALNO3	+0.16%	-0.65%	+15.47%	-11.18%	49.98M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+163.68%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.50%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+82.78%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+37.00%	+30.00%	347B
NOVARTIS AG	-0.60%	+1.52%	+36.67%	+39.80%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+17.29%	+18.19%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-29.09%	-41.29%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.81%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.43%	161B
Average	+0.46%	+1.13%	+25.13%	+46.17%	364.36B
Weighted average by Cap.	+0.76%	+1.95%	+35.99%	+78.72%

	2024	2025
Net sales	417B 15.86M 13.78M 12.94M 11.69M 22.54M 1.53B 22.54M 154M 60.12M 751M 59.7M 58.45M 2.6B	438B 16.64M 14.45M 13.58M 12.26M 23.65M 1.61B 23.65M 161M 63.06M 787M 62.62M 61.31M 2.72B
Net income	121B 4.6M 4M 3.76M 3.39M 6.54M 444M 6.54M 44.59M 17.45M 218M 17.33M 16.96M 753M	156B 5.93M 5.15M 4.84M 4.37M 8.43M 572M 8.43M 57.44M 22.47M 281M 22.32M 21.85M 970M
Net Debt	-342B -12.98M -11.28M -10.59M -9.57M -18.45M -1.25B -18.45M -126M -49.2M -614M -48.86M -47.84M -2.12B	-441B -16.77M -14.56M -13.68M -12.35M -23.82M -1.62B -23.82M -162M -63.53M -793M -63.09M -61.77M -2.74B